LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fully Automated HbA1c Analyzer Available for Inspection at AACC Annual Meeting

By LabMedica International staff writers
Posted on 02 Aug 2016
Image: The cobas c 513 high-throughput HbA1c analyzer (Photo courtesy of Roche).
Image: The cobas c 513 high-throughput HbA1c analyzer (Photo courtesy of Roche).
A fully automated, high-throughput system for HbA1c testing will be available for inspection at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Roche (Basel, Switzerland) will introduce the cobas c 513 analyzer at Booth 1301 of the Philadelphia expo. The c 513 is a fully automated, high-throughput HbA1c testing solution with a module that can reach a throughput of up to 400 determinations per hour. The reagent compartment has 60 reagent positions that can be loaded providing up to 14,000 results.

The instrument features direct results reporting, which minimizes the risk of result misinterpretation and eliminates the need for performing time-consuming, manual result interpretation. This new analyzer also offers closed tube sampling, which reduces hands-on time, prevents sample contamination, and ensures operator safety.

As the instrument is still awaiting FDA 510(k) approval, the c 513 is not currently available in the USA.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Roche
Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
INTEGRA BIOSCIENCES AG